Approaches for discovering anti-prion compounds: Lessons learned and challenges ahead

Expert Opinion on Drug Discovery

Volumn 10, Issue 4, 2015, Pages 389-397

  Bolognesi, Maria Laura ^a   Legname, Giuseppe ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SISSA   (Italy)

Author keywords

doxycycline; neurodegenerative drug discovery; phenotypic screening; prion diseases; protein misfolding diseases; quinacrine

Indexed keywords

ACRIDINE DERIVATIVE; ASTEMIZOLE; DOXYCYCLINE; GUANABENZ; MEPACRINE; PRION PROTEIN; PRION;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG REPOSITIONING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MEDICINAL CHEMISTRY; NEUROBLASTOMA CELL LINE; NONHUMAN; PHENOTYPE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DESIGN; DRUG DEVELOPMENT; METABOLISM; MOUSE; PRION; PRION DISEASES; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MICE; PHENOTYPE; PRION DISEASES; PRIONS; PROTEIN FOLDING;

EID: 84925293016     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1016498     Document Type: Review

References (57)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216(4542): 136-44
2. Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004; 116(2): 313-27
3. Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 2012; 209(5): 889-93
4. Costanzo M, Zurzolo C. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochem J 2013; 452(1): 1-17
5. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012; 336(6088): 1511-13
6. Legname G, Bolognesi ML. Editorial (Thematic issue: Recent advances of biology and medicinal chemistry of prion protein and prions: on the road to therapeutics). Curr Top Med Chem 2013; 13(19): 2395-6
7. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014; 6(4): 37
8. Gravitz L. Drugs: a tangled web of targets. Nature 2011; 475(7355): S9-11
9. Ghose AK, Herbertz T, Hudkins RL, et al. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci 2012; 3(1): 50-68
10. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013; 36(3): 437-49
11. Forloni G, Artuso V, Roiter I, et al. Therapy in prion diseases. Curr Top Med Chem 2013; 13(19): 2465-76
12. Baral PK, Swayampakula M, Rout MK, et al. Structural basis of prion inhibition by phenothiazine compounds. Structure 2014; 22(2): 291-303
13. Alzheimer's Association National Plan Milestone W. Fargo KN, Aisen P, Albert M, et al. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement 2014; 10(5S): S430-S52
14. Braun MM, Farag-El-Massah S, Xu K, et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010; 9(7): 519-22
15. Committee for Orphan Medicinal Products, the European Medicines. Westermark K, Holm BB, Soderholm M, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011; 10(5): 341-9
16. Bodemer W. The use of monoclonal antibodies in human prion disease. Naturwissenschaften 1999; 86(5): 212-20
17. Fernandez-Borges N, Elezgarai SR, Erana H, et al. Animal models for testing anti-prion drugs. Curr Top Med Chem 2013; 13(19): 2504-21
18. Malaga-Trillo E, Sempou E. PrPs: proteins with a purpose: Lessons from the zebrafish. Prion 2009; 3(3): 129-33
19. Ghaemmaghami S, Russo M, Renslo AR. Successes and challenges in phenotypebased lead discovery for prion diseases. J Med Chem 2014; 57(16): 6919-29
20. Lee JA, Uhlik MT, Moxham CM, et al. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem 2012; 55(10): 4527-38
21. Sykes ML, Avery VM. Approaches to protozoan drug discovery: phenotypic screening. J Med Chem 2013; 56(20): 7727-40
22. Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J 2013; 280(23): 5957-80
23. Zhang M, Luo G, Zhou Y, et al. Phenotypic screens targeting neurodegenerative diseases. J Biomol Screen 2014; 19(1): 1-16
24. Korth C, Klingenstein R, Muller-Schiffmann A. Hybrid molecules synergistically acting against protein aggregation diseases. Curr Top Med Chem 2013; 13(19): 2484-90
25. Vilette D. Cell models of prion infection. Vet Res 2008; 39(4): 10
26. Geissen M, Leidel F, Eiden M, et al. From high-Throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease. ChemMedChem 2011; 6(10): 1928-37
27. Reaume AG. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov Today 2012; 8(3): 85-8
28. Cummings JL, Zhong K. Repackaging FDA-Approved drugs for degenerative diseases: promises and challenges. Expert Rev Clin Pharmacol 2014; 7(2): 161-5
29. Bongarzone S, Bolognesi ML. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin Drug Discov 2011; 6(3): 251-68
30. Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapieassociated prion protein accumulation. J Virol 2000; 74(10): 4894-7
31. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98(17): 9836-41
32. Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52(4): 503-6
33. Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 2013; 81(23): 2015-23
34. Ghaemmaghami S, Ahn M, Lessard P, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009; 5(11): e1000673
35. Huang Y, Okochi H, May BC, et al. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 2006; 34(7): 1136-44
36. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2(1): 86-98
37. Karapetyan YE, Sferrazza GF, Zhou M, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci USA 2013; 110(17): 7044-9
38. Bach S, Talarek N, Andrieu T, et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003; 21(9): 1075-81
39. Tribouillard-Tanvier D, Beringue V, Desban N, et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 2008; 3(4): e1981
40. Tribouillard-Tanvier D, Dos Reis S, Gug F, et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 2008; 3(5): e2174
41. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92(7): 2959-63
42. Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997; 276(5315): 1119-22
43. Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000; 300(5): 1309-22
44. Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002; 99(16): 10849-54
45. Haik S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13(2): 150-8
46. Geschwind MD. Doxycycline for Creutzfeldt-Jakob disease: a failure, but a step in the right direction. Lancet Neurol 2014; 13(2): 130-2
47. Aube J. Drug repurposing and the medicinal chemist. ACS Med Chem Lett 2012; 3(6): 442-4
48. Cope H, Mutter R, Heal W, et al. Synthesis and SAR study of acridine, 2-methylquinoline and 2-phenylquinazoline analogues as anti-prion agents. Eur J Med Chem 2006; 41(10): 1124-43
49. Nguyen TH, Lee CY, Teruya K, et al. Antiprion activity of functionalized 9-Aminoacridines related to quinacrine. Bioorg Med Chem 2008; 16(14): 6737-46
50. Villa V, Tonelli M, Thellung S, et al. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity. Neurotox Res 2011; 19(4): 556-74
51. Nguyen T, Yang T, Go ML. Functionalized acridin-9-yl phenylamines protected neuronal HT22 cells from glutamate-induced cell death by reducing intracellular levels of free radical species. Bioorg Med Chem Lett 2014; 24(7): 1830-8
52. Staderini M, Legname G, Bolognesi ML, et al. Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. Curr Top Med Chem 2013; 13(19): 2491-503
53. May BC, Fafarman AT, Hong SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-Acridines. Proc Natl Acad Sci USA 2003; 100(6): 3416-21
54. Bongarzone S, Tran HN, Cavalli A, et al. Parallel synthesis, evaluation, and preliminary structure-Activity relationship of 2, 5-diamino-1, 4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem 2010; 53(22): 8197-201
55. Nguyen PH, Hammoud H, Halliez S, et al. Structure-Activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost alpha2-Adrenergic receptor agonistic activity. ACS Chem Neurosci 2014; 5(10): 1075-82
56. Colby DW, Zhang Q, Wang S, et al. Prion detection by an amyloid seeding assay. Proc Natl Acad Sci USA 2007; 104(52): 20914-19
57. Wilham JM, Orru CD, Bessen RA, et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 2010; 6(12): e1001217